DDInter1802 DDInter1658
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Ticagrelor {u} (Compound) treats {v} (Disease) coronary artery disease
Ticagrelor {u} (Compound) binds {v} (Gene) ABCB1
Ticagrelor {u} (Compound) is included by {v} (Pharmacologic Class) Phenylalanine Hydroxylase Activators
Ticagrelor {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Ticagrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Ticagrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nifedipine
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lepirudin
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Ticagrelor {u} may lead to a major life threatening interaction when taken with {v} Indinavir
Ticagrelor {u} may lead to a major life threatening interaction when taken with {v} Relugolix
Ticagrelor (Compound) treats coronary artery disease (Disease)
Ticagrelor (Compound) binds ABCB1 (Gene)
Ticagrelor (Compound) is included by Phenylalanine Hydroxylase Activators (Pharmacologic Class)
Ticagrelor (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect)
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Clove
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Nifedipine
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Ticagrelor may lead to a major life threatening interaction when taken with Indinavir
Ticagrelor may lead to a major life threatening interaction when taken with Relugolix